Syringe Driver Survey Database migration to MedicinesComplete - January 2023
Syringe Driver Survey Database has moved to MedicinesComplete and is no longer available on palliativedrugs.com.
It has been renamed to PCF’s Syringe Driver Database and is now accessed through Drug Compatibility Checker.
Drug Compatibility Checker, through MedicinesComplete is a new tool providing essential compatibility knowledge to support the administration of injectable drugs combining published data and clinical practice reports.
Find out more about Drug Compatibility Checker:https://about.medicinescomplete.com/publication/drug-compatibility-checker/
If you have a subscription to Palliative Care Formulary through MedicinesComplete, you will have access to PCF’s Syringe Driver Database through Drug Compatibility Checker, at no charge through 2023.
To contribute to PCF’s Syringe Driver Database please continue to submit a clinical practice report using palliativedrugs.com here: https://www.palliativedrugs.com/syringe-driver-database.html
To learn more about a subscription to the Palliative Care Formulary through MedicinesComplete, please contact us here: https://info.medicinescomplete.com/sales
If you have any questions regarding access to PCF’s Syringe Driver Database or would like to renew your subscription to Palliative Care Formulary, please contact pharmpress-support@rpharms.com.
Gabapentin and pregabalin consultation on proposals to schedule under Misuse of Drugs Regulations
14th November 2017
The government have opened a consultation on proposals to schedule gabapentin and pregabalin under the Misuse of Drugs Regulations 2001. The preferred option, as recommended by the Advisory Council on the Misuse of Drugs (ACMD) is that these drugs should be controlled as Class C drugs (under the Misuse of drugs Act 1971) and placed in Schedule 3 (to the Misuse of Drugs Regulations 2001). Comments are welcome from all interested parties by 22 January 2018.
Recent news
- Palliative Care Formulary available via the Association for Palliative Medicine (APM)
- NICE draft guideline for cannabidiol for Dravet syndrome
- NICE draft guideline for cannabidiol for Lennox-Gastaut syndrome
- NICE draft guideline for Cannabis-based medicinal products
- EMA adopts a positive opinion for Epidyolex
- Updated BTS/SIGN asthma guideline published
- Joint position statement on the decision by WHO to withdraw guidance documents
- Neuropathic pain in adults: updated NICE guidance
- BETTER- B breathlessness survey- last chance to complete
- Safer management of controlled drugs
News archive
- 2020
- 2019
- 2018
- 2017
- 2016
- 2015
- 2014
- 2013
- 2012
- 2011
- 2010
- 2009
- 2008
- 2008
- 2007
- 2006
- 2005
- 2004
- 2003
- 2002
- 2001
- 2000